Asset Details
Do you wish to reserve the book?
Toward a biological definition of neuronal and glial synucleinopathies
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Toward a biological definition of neuronal and glial synucleinopathies
Do you wish to request the book?
Toward a biological definition of neuronal and glial synucleinopathies
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Toward a biological definition of neuronal and glial synucleinopathies
2025
Overview
Cerebral accumulation of alpha-synuclein (αSyn) aggregates is the hallmark event in a group of neurodegenerative diseases—collectively called synucleinopathies—which include Parkinson’s disease, dementia with Lewy bodies and multiple system atrophy. Currently, these are diagnosed by their clinical symptoms and definitively confirmed postmortem by the presence of αSyn deposits in the brain. Here, we summarize the drawbacks of the current clinical definition of synucleinopathies and outline the rationale for moving toward an earlier, biology-anchored definition of these disorders, with or without the presence of clinical symptoms. We underscore the utility of the αSyn seed amplification assay to detect aggregated αSyn in living patients and to differentiate between neuronal or glial αSyn pathology. We anticipate that a biological definition of synucleinopathies, if well-integrated with the current clinical classifications, will enable further understanding of the disease pathogenesis and contribute to the development of effective, disease-modifying therapies.
Parkinson’s diseases and other synucleinopathies are on the verge of a major paradigm shift toward being defined and staged by their biology, rather than symptoms; this Perspective offers context on progress, needs and opportunities toward this goal.
Publisher
Nature Publishing Group US,Nature Publishing Group
Subject
/ alpha-Synuclein - metabolism
/ Animals
/ Atrophy
/ Autopsy
/ Biology
/ Biomedical and Life Sciences
/ Disease
/ Humans
/ Lewy Body Disease - metabolism
/ Lewy Body Disease - pathology
/ Medicinska och farmaceutiska grundvetenskaper
/ Multiple System Atrophy - metabolism
/ Multiple System Atrophy - pathology
/ Parkinson Disease - metabolism
/ Parkinson Disease - pathology
/ Synucleinopathies - diagnosis
